Surrozen (NASDAQ:SRZN) Rating Increased to Strong-Buy at William Blair

William Blair upgraded shares of Surrozen (NASDAQ:SRZNFree Report) to a strong-buy rating in a research report released on Thursday, MarketBeat reports. William Blair currently has $51.00 price target on the stock.

Several other equities analysts also recently commented on the stock. Zacks Research raised shares of Surrozen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. HC Wainwright restated a “buy” rating and set a $44.00 price target on shares of Surrozen in a report on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.00.

View Our Latest Stock Report on SRZN

Surrozen Stock Down 2.1%

SRZN opened at $23.50 on Thursday. The business’s fifty day simple moving average is $23.10 and its 200 day simple moving average is $25.64. Surrozen has a 52 week low of $10.73 and a 52 week high of $35.00. The stock has a market cap of $272.83 million, a PE ratio of -0.58 and a beta of 0.52.

Surrozen (NASDAQ:SRZNGet Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.88. The business had revenue of $5.00 million for the quarter, compared to the consensus estimate of $0.47 million. As a group, equities analysts anticipate that Surrozen will post -7.62 earnings per share for the current year.

Insider Buying and Selling at Surrozen

In related news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the stock in a transaction on Wednesday, July 22nd. The stock was sold at an average price of $21.25, for a total transaction of $6,906,250.00. Following the sale, the insider owned 574,047 shares in the company, valued at approximately $12,198,498.75. This represents a 36.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 31.74% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SRZN. Geode Capital Management LLC boosted its stake in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the period. Armistice Capital LLC bought a new stake in shares of Surrozen during the second quarter worth $536,000. Vanguard Group Inc. boosted its stake in shares of Surrozen by 21.7% during the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after purchasing an additional 47,468 shares during the period. Acuta Capital Partners LLC boosted its stake in shares of Surrozen by 5.0% during the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after purchasing an additional 8,415 shares during the period. Finally, Schonfeld Strategic Advisors LLC bought a new position in shares of Surrozen in the third quarter worth about $889,000. Institutional investors own 66.57% of the company’s stock.

About Surrozen

(Get Free Report)

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.

Featured Stories

Analyst Recommendations for Surrozen (NASDAQ:SRZN)

Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.